Brigham Heart & Vascular Faculty at AHA Scientific Sessions 2023

Audience Full of People in Dark Conference Hall Watching Keynote Presentation

For the past 100 years, the American Heart Association (AHA) has advocated for the growth of cardiovascular science. The annual AHA Scientific Sessions event brings together thousands of international colleagues to share the latest cardiovascular research and clinical practice advancements.

This year marks the 76th anniversary of the sessions. On November 11—13, 2023, thousands of delegates will converge in person in Philadelphia, PA, or virtually to review topics such as the latest heart failure guidelines, strategies to promote equitable healthcare, profiles in cardiovascular diseases, and more.

Brigham and Women’s Hospital will have a strong presence at this year’s event, with many experts from the Heart and Vascular Center set to present their research and evidence-driven clinical recommendations. The Brigham is proud to present alongside other cardiovascular experts from across the globe.

Learn more and register for the event here.

Brigham Participants

Caroline Apovian, MD

Obesity – Novel Therapeutics and Implications for Population Health

Mostafa Al-Alusi, MD

Deep Learning-based Digital Biomarker to Diagnose Hypertension and Stratify Cardiovascular Risk From the Electrocardiogram

Marc Bonaca, MD, MPH

Stem Cell Factor Associated With Critical Limb Ischemia in Patients With Peripheral Artery Disease

John Bertot, MD, MPH

Predictive Utility of a CAD Polygenic Risk Score in a Low-risk Primary Prevention Cohort

Anthony Carnicelli, MD

Characteristics and Outcomes of Patients With Clinically Significant Valvular Heart Disease and Cardiogenic Shock Admitted to Cardiac Intensive Care Units

Christine Chow

Association of Hemoglobin With Mortality Outcomes in the Critical Care Cardiology Trials Network (CCCTN) Registry

Jonathan Cunningham, MD

Natural Language Processing for Adjudication of Heart Failure Hospitalizations in a Multi-Center Clinical Trial

Prakriti Gaba, MD

  • Intraindividual Variability in Serial Lipoprotein(a) Concentration Among Placebo-treated Patients in the OCEAN(a)-DOSE Trial
  • Association Between Achieved Low-density Lipoprotein Cholesterol Levels and Long-term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE

Shinichi Goto, MD, PhD

A Multinational Federated Learning Approach to Train Electrocardiogram and Echocardiogram Models for Hypertrophic Cardiomyopathy Detection

Ameesh Isath, MD

MICU Overflow Patients in the Cardiac Intensive Care Unit: Insights From the Critical Care Cardiology Trials Network Registry

Yuri Kim, MD, PhD

Genetics in Cardiotoxicity Risk Stratification: Ready for Prime Time?

Sheila Klassen, MD

Linking PEN-Plus Heart Failure Care With Access to Cardiac Surgery

Mandeep Mehra, MD

Heart Failure – VADs, Kids, and Money

Daniel McClintick, MD

Long-term Efficacy of Evolocumab in Patients With and Without Multivessel Coronary Artery Disease

Michelle O’Donoghue, MD, MPH

  • The Latest Advances in Lipid Lowering Therapies
  • A New Era: Emerging Therapeutic Strategies for Lowering Lp(a)
  • Future of Lipid Lowering Therapy – Novel Mechanisms and Approaches

Patrick O’Gara, MD

  • Perspective From AHA/ACC Guidelines on How the Societies Can Reconcile Differences on Coronary Revascularization
  • Lifetime Management of Aortic Valve Disease: Challenges and New Horizons
  • 2023 James B. Herrick Award for Outstanding Achievement in Clinical Cardiology

Jorge Plutzky, MD

  • Steering Committee and Co-author for the Landmark Trial That Is a Primary Focus for the AHA SELECT, Showing Weight Loss Drug Semaglutide Decreases CV Events in Those Who Are
  • Overweight and Have Risk for CV Disease But Do Not Have Diabetes

Paul Ridker, MD, MPH

Presenting Data From >13,000 Contemporary Patients That the Inflammatory Biomarker (hsCRP) Predicts Future CV Events More Strongly Than Cholesterol (LDLC)

Christian Ruff, MD, MPH

  • Study Confirming Overwhelming Reduction in Bleeding of the Dual-acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban
  • Abelacimab, a Novel Factor XI/XIa Inhibitor, vs. Rivaroxaban in Patients With Atrial Fibrillation: Primary Results of the AZALEA-TIMI 71 Randomized Trial

Benjamin Scirica, MD

Power to the People (Allow Non-MDs to Most Medical Conditions)

Sachit Singal, MD

  • Modes of In-hospital Death in Patients With Cardiogenic Shock (CS): An Analysis From the Critical Care Cardiology Trials Network (CCCTN)
  • CAD Polygenic Risk Score and Incident Complex Coronary Revascularization in Adults With Atherosclerosis

Sasha Singh, PhD

Workshop on Proteomics: Designing Proteomics for Basic Research

Stephanie Skove, MD

Early Evolution of SCAI-Shock Stage and In-hospital Mortality in a CICU Population From the Critical Care Cardiology Trials Network (CCCTN)

Viviany Taqueti, MD, MPH

Artificial Intelligence at the Bedside

Stephen Wiviott, MD

Hot Topics in Management of Coronary Artery Disease/Acute Coronary Syndrome

Fred Wu, MD

Poster: Hemodynamic Effects of External Counterpulsation in Patients With Fontan Circulation

Andre Zimerman, MD, PhD

  • Long-term Neurocognitive Safety of LDL-C Lowering With Evolocumab: Open-label Extension Data From FOURIER
  • Performance of a Polygenic Risk Score for Coronary Artery Disease Across the Spectrum of ASCVD: An Analysis of 60k Patients From 6 TIMI Randomized Trials

Leave a Reply